Guardant Health (GH) Earnings Analysis

Guardant Health (GH) next reports earnings on 2026-07-30, consensus EPS -0.41 USD. Last quarter (2026-05-07) it missed with EPS -0.85 USD vs -0.806 USD est (-5.5%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E -44.47.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does GH next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate-0.41 USD
Revenue estimate0.31B

GH earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.85 USD-0.806 USD-5.5%Miss
2026-02-19-0.9 USD-0.76677 USD-17.4%Miss
2025-07-30-0.44 USD-0.52 USD+15.4%Beat
2025-04-30-0.49 USD-0.61 USD+19.7%Beat
2025-02-20-0.62 USD-0.75 USD+17.3%Beat

Beat rate: 3/5 (60%) over reported quarters with consensus data.

GH valuation and analyst view

Trailing P/E-44.47
Trailing EPS-3.29994 USD
Price / book-109.29
Dividend yield0.00%
Market cap19.81B
Analyst consensusBuy (29 buy / 0 hold / 1 sell)
Avg price target170.75 USD

Related research pages

Frequently asked questions

When is Guardant Health (GH)'s next earnings date?

Guardant Health is next scheduled to report on 2026-07-30, with a consensus EPS estimate of -0.41 USD and revenue estimate of 0.31B.

Did GH beat earnings last quarter?

In its 2026-05-07 report, GH posted EPS of -0.85 USD versus a -0.806 USD estimate — a miss of 5.5%.

What is GH's earnings track record?

Over the last 5 reported quarters with consensus data, GH beat estimates 3 times (60%).

What is GH's current P/E ratio and EPS?

GH trades at a trailing P/E of -44.47 on trailing EPS of -3.2999398200696257 USD.

What do analysts rate GH?

Analyst consensus is "Buy" across 30 ratings (0 strong buy, 29 buy, 0 hold, 1 sell, 0 strong sell). Average 12-month price target: 170.75 USD.